- Home
- RPTX vs XFOR Comparison
RPTX vs XFOR Comparison
Compare RPTX & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- XFOR
- Stock Information
- Founded
- RPTX 2016
- XFOR 2014
- Country
- RPTX Canada
- XFOR United States
- Employees
- RPTX N/A
- XFOR N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPTX Health Care
- XFOR Health Care
- Exchange
- RPTX Nasdaq
- XFOR Nasdaq
- Market Cap
- RPTX 69.2M
- XFOR 84.3M
- IPO Year
- RPTX 2020
- XFOR N/A
- Fundamental
- Price
- RPTX $1.74
- XFOR $3.04
- Analyst Decision
- RPTX Strong Buy
- XFOR Strong Buy
- Analyst Count
- RPTX 3
- XFOR 3
- Target Price
- RPTX $4.50
- XFOR $34.17
- AVG Volume (30 Days)
- RPTX 96.5K
- XFOR 1.0M
- Earning Date
- RPTX 11-06-2025
- XFOR 11-12-2025
- Dividend Yield
- RPTX N/A
- XFOR N/A
- EPS Growth
- RPTX N/A
- XFOR N/A
- EPS
- RPTX N/A
- XFOR N/A
- Revenue
- RPTX $250,000.00
- XFOR $32,774,000.00
- Revenue This Year
- RPTX N/A
- XFOR $1,313.84
- Revenue Next Year
- RPTX N/A
- XFOR N/A
- P/E Ratio
- RPTX N/A
- XFOR N/A
- Revenue Growth
- RPTX N/A
- XFOR 5721.31
- 52 Week Low
- RPTX $0.89
- XFOR $1.35
- 52 Week High
- RPTX $4.07
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- RPTX 62.38
- XFOR 48.54
- Support Level
- RPTX $1.66
- XFOR $2.88
- Resistance Level
- RPTX $1.83
- XFOR $3.79
- Average True Range (ATR)
- RPTX 0.06
- XFOR 0.38
- MACD
- RPTX 0.00
- XFOR -0.12
- Stochastic Oscillator
- RPTX 64.00
- XFOR 10.76
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.